Axogen, Inc. (AXGN) filed a Form 8-K on November 9, 2026, to furnish a corporate presentation regarding its expansion into the prostate nerve reconstruction market. The presentation details the clinical experience and market potential for using Avance nerve graft in treating erectile dysfunction following prostate surgery.
The company highlighted the significant impact of erectile dysfunction and incontinence on patient quality of life. According to Axogen’s data, approximately 14% to 90% of robotic-assisted radical prostatectomies require the complete removal of one or both nerve bundles. The presentation cites a 2026 FSI-Axogen patient survey indicating that 87% of patients reported that changes in erectile function affected their quality of life, while 95% believe doctors should do everything possible to preserve or restore erectile function.
Axogen outlined a Total Addressable Market (TAM) of $754 million for prostate nerve reconstruction. The company estimates there are approximately 110,000 prostatectomy cases per year in the U.S., with a weighted average selling price of approximately $7,000 per procedure for nerve reconstruction. The company cited market research suggesting that 78% of radiation patients and 76% of active surveillance patients would have been more likely to choose surgery if nerve reconstruction was an option.
The presentation included clinical data from Dr. Tung Shu at the Vanguard Urologic Institute. According to the data, over 220 patients have been reconstructed with Avance, with 117 patients treated and followed for at least six months. The results showed that approximately 80% of patients had better than expected erectile function, and over 95% returned to continence. The company also noted that a study by Dr. Shu found recovery of erectile function was higher following nerve reconstruction than in published historical controls.
